Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 10 January 2018

Biocartis Group NV: Disclosure of a transparency notification

Biocartis Group NV    

Published: 07:00 CET 10-01-2018 /GlobeNewswire /Source: Biocartis Group NV / : BCART /ISIN: BE0974281132

Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION
10 January 2018, 07:00 CET


Disclosure of a transparency notification
(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)


Mechelen, Belgium, 10 January 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that on 8 January 2018 it received a transparency notification dated 20 December 2017 (the 'Notification'), indicating that the shareholding of Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) has decreased below the 10% notification threshold. It concerns a passive downward crossing of the 10% notification threshold. As a result, Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) now holds 8.32% of the voting rights in Biocartis. 

The Notification contains the following information:

· Reason for the Notification: Acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer. Passive crossing of a threshold.

· Notification by: A parent undertaking or a controlling person. 

· Persons subject to the notification requirement: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.), Rue du Levant 146, 1920 Martigny, Switzerland; Debiopharm Holding S.A., Rue du Levant 146, 1920 Martigny, Switzerland; Thierry Mauvernay, Chemin du Praz-Buchilly 113, 1000 Lausanne 25, Switzerland.

· Transaction date: 28 November 2017.

· Threshold that is crossed: 10%.

· Denominator: 51,069,772.

· Details of the Notification: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.)  holds 4,249,707 voting rights.

· Full chain of controlled undertakings through which the holding is effectively held: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) is controlled by Debiopharm Holding S.A., which is controlled by Thierry Mauvernay. 

· Additional information: There was a transfer of controlling person and beneficial owner from Rolland-Yves Mauvernay to Thierry Mauvernay. 

The Notification is available here on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.


----- END ----

More information: 
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
email rdegrave@biocartis.com 
tel +32 15 631 729 | mobile +32 471 53 60 64 
 

About Biocartis 
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers twelve oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla(TM) trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. 


Forward-looking statements 

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Biocartis Group NV, Generaal De Wittelaan 11 b3, Mechelen 2800, Belgium
If you would like to unsubscribe and stop receiving these e-mails click here.